Stairmed, a company focused on developing advanced brain-machine interfaces, has secured $72.5 million in new funding. This significant investment round is set to accelerate the company's efforts in bringing its innovative neurotechnology to clinical use.
The company specializes in building minimally invasive, chronically stable brain–machine interfaces. Stairmed's systems feature ultrafine, ultraflexible electrodes, which are as narrow as one-fifth the width of a human hair. A key innovation is its built-in brain implant, engineered to be exceptionally thin, which does not require the complete removal of a section of the skull. This design further minimizes tissue damage and allows for stable, high-fidelity neural recording over long periods. Stairmed's mission is to decode intention, restore function, and eventually integrate brain–machine interfaces into the everyday lives of the public.
This substantial capital infusion underscores investor confidence in Stairmed's unique technological approach and its potential to revolutionize neuroprosthetics. The newly raised funds will be strategically deployed to advance ongoing research and development initiatives, expand the scope and scale of clinical trials, and enhance manufacturing capabilities. These efforts are crucial for progressing Stairmed's systems from their current developmental stage into broader clinical application, aiming to meet the high demand for advanced neural interface solutions.
The funding positions Stairmed to further its mission of designing brain-machine interfaces that respect the brain’s biology while expanding its capabilities. By accelerating its development roadmap, the company aims to drive significant advancements in the field, ultimately working towards making sophisticated neurotechnology accessible and impactful for a wider population and integrating these solutions into daily life.
